drugset / Trial / NCT06756126
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
Timeline
- Start
- 2024-12-30
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK120 | Monoclonal antibody | 300 mg | Subcutaneous |